ArticleResearch in pharmaceutical sciences2025
Apoptotic effect of linifanib on human ovarian cancer OVCAR3 cell line.
Article in Research in pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Linifanib is a multi-targeted receptor tyrosine kinase inhibitor. Although it is widely recognized for its efficacy in inhibiting receptor tyrosine kinases, its anticancer effects in ovarian cancer have not been extensively studied. In this study, we investigated the anticancer effects of linifanib on human ovarian cancer OVCAR3 cells. Experimental approach: To evaluate cell proliferation capacity, we performed MTT assays, cell counting, morphological analysis, and colony formation assays. Flow cytometry was used to assess the induction of apoptotic cells by linifanib, and DNA fragmentation was evaluated using TUNEL assays. Western blotting was performed to determine the protein expression levels related to apoptosis. Findings/Results: Our results demonstrated that linifanib significantly inhibited the proliferation of OVCAR3 cells and induced apoptosis. Notably, treatment with linifanib led to the inhibition of phosphorylated Akt at Ser473, accompanied by the activation of FOXO3. Conclusion and implications: Taken together, these findings indicate that linifanib suppresses the proliferation of human ovarian cancer OVCAR3 cells, highlighting its potential as a therapeutic candidate for ovarian cancer treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.